{
    "2018-10-15": [
        [
            {
                "time": "2018-10-15",
                "original_text": "IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "Class Action",
                        "Lawsuit",
                        "AbbVie Inc.",
                        "Investors",
                        "Losses"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV",
                "features": {
                    "keywords": [
                        "Shareholder Alert",
                        "Pomerantz Law Firm",
                        "AbbVie Inc.",
                        "Class Action",
                        "Lawsuit"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "features": {
                    "keywords": [
                        "Class Action",
                        "Update",
                        "COCP",
                        "ABBV",
                        "ALNY",
                        "Investors"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "Merck Is Expected to Record Steady Revenue Growth in Q3",
                "features": {
                    "keywords": [
                        "Merck",
                        "Revenue Growth",
                        "Q3"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "Company News For Oct 15, 2018",
                "features": {
                    "keywords": [
                        "Company News",
                        "Oct 15, 2018"
                    ],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "AbbVie Inc. Investor Alert: Law Offices of Andrew J. Brown Investigates Possible Breaches of Fiduciary Duty by Officers and Directors",
                "features": {
                    "keywords": [
                        "AbbVie Inc.",
                        "Investor Alert",
                        "Fiduciary Duty",
                        "Officers",
                        "Directors"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better",
                "features": {
                    "keywords": [
                        "Pharmaceutical Stocks",
                        "Buy",
                        "Dividends",
                        "3%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed",
                "features": {
                    "keywords": [
                        "Health Canada",
                        "Label Update",
                        "AbbVie",
                        "HUMIRA®",
                        "Breastfeeding",
                        "Pregnancy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}